Abstract
“The Chair” is a series that explores important contemporary issues such as cancel culture, institutional racism, sexism, and ageism in the context of a university setting. The series follows the story and struggles of Professor Ji-Yoon Kim, the first woman, and an Asian-American, to be appointed chair of the English department at the elite Pembroke University, as she tries to protect the employment of a young African-American female professor and to raise her adopted daughter as a harried single parent. This media review essay examines the themes and issues addressed in this TV series, including the challenges faced by women and the ways in which traditional models of education may be inadequate for engaging and retaining the interest of younger generations. The review essay suggests that this TV series could serve as a starting point for considering how issues of bias, cultural shifts, and commercial pressures play out in a university setting, and encourages further exploration and discussion of these important topics.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Ramos, Manoella Antonieta
(2023)
"Market-driven Pressures and Institutional Biases at a University: A Review of the TV series The Chair,"
Markets, Globalization & Development Review:
Vol. 8:
No.
1, Article 3.
DOI: 10.23860/MGDR-2023-08-01-03
Available at:
Included in
Classics Commons, Digital Humanities Commons, Educational Leadership Commons, Higher Education Commons, Modern Languages Commons, Nonprofit Administration and Management Commons
Author Bio
Manoella Antoneita Ramos is a Marie Skłodowska-Curie early-stage researcher (ESR 2) within the LNETN project, based at Halmstad University, Sweden. In her research, Manoella examines how institutional contexts and policies shape and are shaped by the emergence, legitimation and internationalization processes of life science industries (such as medical technology, pharmaceuticals and biotechnology). This includes, but is not limited to, an international product launch that is a complex endeavour, scaling up marketing and sales, expensive and difficult clinical trials, regulatory demands, in gaining access to hospitals and doctors and financing the complete R&D process.